Market
Analysis:
Growing approval of medicines that are patient centric and
personalized have added further impetus to the growth of the industry in the
forecast period. The state of the medicine sector recently has created ample
opportunities for the development of the market. High rates of approval for
biologics have been the motivating factors behind the expansion of the market.
Increased resistance to conventional drugs has prompted manufacturers to explore
and invest in other opportunities. Rising number of market players will prompt
improved growth of the market, especially through the forecast period.
Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/1339
The
global biologics market is anticipated to touch USD 285,520.4 million at a
6.95% CAGR between 2018-2023,
states the new Market Research Future (MRFR) report. Biologics, simply put, are
made from materials that come from various living organisms such as animals,
humans, and microorganisms, namely yeast or bacteria. Usually, biological
products are manufactured, utilizing biotechnology methods or other advanced
technologies. They are widely used for providing effective treatment for
several complex diseases, including Crohn’s disease, psoriasis, and rheumatoid
arthritis, which have limited options for treatment. Biologics is transforming
the manner in which physicians treat common conditions that have plagued people
for years. They have many potential benefits as; theoretically, they can be
customized for hitting particular gene targets in the body.
Numerous
factors are propelling the Biologics Market Size Such
factors, as per the new Market Research Future report, include unremitting
research & development activities, rising regulatory convergence,
increasing government initiatives in the healthcare sector, growing demand as
well as higher acceptability of innovative therapies, and the emergence of
orphan drugs and personalized medicines. Additional factors propelling the
growth of the biologics market include improvement in the healthcare
infrastructure, rapid urbanization, increasing awareness about the efficacy and
performance of biologics, and increasing prevalence of different chronic
diseases.
Key
Players :
Notable
players profiled in the biologics market report include GlaxoSmithKline Plc
(UK), Eli Lilly and Company (US), Bayer AG (Germany), Sanofi (France), F.
Hoffman-La Roche AG (Switzerland), Novartis AG (Switzerland), Amgen (US),
Pfizer Inc. (US), AstraZeneca (UK), and AbbVie, Inc. (US). Key players have
incorporated specific strategies to increase their market share, such as
acquisitions, expansions, and new product launches.
Market
Segmentation:
·
The Market Research Future report offers a complete segmental
analysis of the biologics market based on manufacturing, disease indication,
and product.
·
Based on product, the global biologics market is segmented into
gene therapy, growth factors, vaccines, interleukins, monoclonal antibody, and
others. Of these, the monoclonal antibody segment will have the largest share
in the market during the forecast period for its increasing use for enhancing
the body’s immunity system.
·
Based on disease indication, the biologics market is segmented
into diabetes, cancer, psoriasis/psoriatic arthritis, rheumatoid arthritis, and
others. Of these, the cancer segment dominated the market in 2018, but
rheumatoid arthritis is predicted to dominate the biologics market over the
forecast period for the rapid approval of different drugs by the regulatory
agencies.
·
Based on manufacturing, the biologics market is segmented into outsourced
and in-house. Of these, the outsourced segment will have the maximum share in
the market during the forecast period for the presence of several
pharmaceutical companies, especially in developing countries.
Regional
Analysis:
By
region, the biologics market report covers the latest trends and growth
opportunities across the Americas, the Asia Pacific, Europe, and the Middle
East and Africa. Of these, the Americas will dominate the market during the
forecast period. Various factors are propelling the growth of the biologics
market in the region, such as investments in new facilities for producing drugs
for clinical trials, strong economic growth of Canada and the US, and rapid
adoption of manufacturing technologies. It is predicted to touch USD 129,652.7
million at a 4.31% CAGR.
The
biologics market in the APAC region will grow at the fastest pace during the
forecast period. Various factors are propelling the growth of the biologics
market in the region, such as the changing healthcare sector, increasing
geriatric populace, and the presence of different contract manufacturing
organizations (CMOs) in the region. India is a major contributor in this region
for its massive strides in biologics manufacturing.
Industry
News
December
2019: Researchers at the Shenzhen Institutes of Advanced Technology, China, and
Duke University, US, have created a platform that will make the biologics
production process simpler.
NOTE : Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details
No comments:
Post a Comment